摘要
目的观察新型免疫抑制剂来氟米特(商品名:爱若华)治疗过敏性紫癜肾炎的疗效和安全性。方法经肾活检证实的过敏性紫癜肾炎住院患者62例,同期按1∶1随机分为来氟米特实验组和常规治疗对照组(雷公藤多甙和环磷酰胺)各31例,总疗程6个月,观察治疗前后24h尿蛋白定量、尿红细胞计数等指标变化,按照疗效评定标准对比分析来氟米特实验组与常规治疗对照组的疗效和安全性。结果①实验组24h尿蛋白定量、尿红细胞计数较治疗前明显下降,由(3.11±3.02)g降至(0.12±0.16)g,(967±654)个/滋l降至(18±6)个/滋l,下降幅度明显高于对照组[(3.26±3.14)g降至(0.31±0.27)g,(946±673)个/滋l降至(24±17)个/滋l],P<0.01;②总有效率实验组为100%,对照组为87.1%,两组疗效比较差异有显著性(P<0.01);③副作用发生率实验组12.9%(4/31),对照组61.3%(19/31)。结论来氟米特作为一种新型免疫抑制剂治疗HSPGN较常规治疗起效快、疗程短、疗效好、副作用少,值得临床推广应用。
Objective To observe the effect and security of leflunomide as a new immuno-suppressive drug on Henoch Schonlein purpura nephritis.Methods Sixty-two patients of Henoch Schonlein purpura nephritis were divided into 2 groups randomly.All the patients were diagnosed by renal biopsy.Test group was treated with leflunomide and control group was treated with routine method (tripterygium glycosides and cyclophosphamide).All the patients were treated for 6 months.The change of markers such as quantity of urinary protein and urinary RBC before and after treatment was analyzed.The effect and security of the two groups were compared and analyzed according to the standard of effect evaluation.Results ①The urinary protein excretion decreased significantly [from (3.11±3.02) g to (0.12±0.56) g] and the same as urinary RBC [from(967±654)/靗 to(18靗) in test group after treatment, obviously greater than those in the control group [from (3.26靗 to(24靗), P<0.01.②The total effective rate of test group was 100% and that of control group was 87.1%,there was a very significant difference between two groups, P<0.01.③The adverse reaction rate was 12.9% (4/31) in test group and 61.3% (19/31) in control group.Conclusion Leflunomide as a new immuno-suppressive drug is obviously superior to routine medicines in the treatment of Henoch Schonlein purpura nephritis.S醝nce the method can offer a quick action with good result and lower adverse reaction, it worth being widely used in clinic.
出处
《中国药物与临床》
CAS
2004年第5期350-352,共3页
Chinese Remedies & Clinics
